JP2022552371A - 免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用 - Google Patents

免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用 Download PDF

Info

Publication number
JP2022552371A
JP2022552371A JP2022522628A JP2022522628A JP2022552371A JP 2022552371 A JP2022552371 A JP 2022552371A JP 2022522628 A JP2022522628 A JP 2022522628A JP 2022522628 A JP2022522628 A JP 2022522628A JP 2022552371 A JP2022552371 A JP 2022552371A
Authority
JP
Japan
Prior art keywords
seq
lnp
molecule
amino acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552371A5 (https=
JPWO2021076805A5 (https=
Inventor
エリック イー－チュン フアン，
ジャレッド イアコヴェッリ，
ピチョット， シーモア デ
ジィー－ワー ツェ，
ローリー ケニー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2022552371A publication Critical patent/JP2022552371A/ja
Publication of JP2022552371A5 publication Critical patent/JP2022552371A5/ja
Publication of JPWO2021076805A5 publication Critical patent/JPWO2021076805A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022522628A 2019-10-15 2020-10-15 免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用 Pending JP2022552371A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962915304P 2019-10-15 2019-10-15
US62/915,304 2019-10-15
US202062959716P 2020-01-10 2020-01-10
US62/959,716 2020-01-10
US202063017040P 2020-04-29 2020-04-29
US63/017,040 2020-04-29
PCT/US2020/055844 WO2021076805A1 (en) 2019-10-15 2020-10-15 Mrnas encoding immune modulating polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2022552371A true JP2022552371A (ja) 2022-12-15
JP2022552371A5 JP2022552371A5 (https=) 2023-10-24
JPWO2021076805A5 JPWO2021076805A5 (https=) 2023-10-24

Family

ID=73402111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522628A Pending JP2022552371A (ja) 2019-10-15 2020-10-15 免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用

Country Status (6)

Country Link
US (1) US20240158458A1 (https=)
EP (1) EP4045527A1 (https=)
JP (1) JP2022552371A (https=)
AU (1) AU2020368447A1 (https=)
CA (1) CA3157859A1 (https=)
WO (1) WO2021076805A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240042015A1 (en) 2020-05-19 2024-02-08 Orna Therapeutics, Inc. Circular rna compositions and methods
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
AU2022273530A1 (en) * 2021-05-12 2023-11-23 Massachusetts Institute Of Technology Modified mrna, modified non-coding rna, and uses thereof
CN118302435A (zh) * 2022-02-18 2024-07-05 江苏众红生物工程创药研究院有限公司 一种实现生物活性分子其活性控释和缓释的方法及药物应用
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024129826A2 (en) * 2022-12-14 2024-06-20 Grann Pharmaceuticals Inc. Compositions and methods for modulating hsp70 activity
EP4680728A1 (en) * 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
WO2024240962A1 (en) * 2023-05-25 2024-11-28 Ethris Gmbh Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
WO2025024674A2 (en) * 2023-07-26 2025-01-30 Promab Biotechnologies, Inc. Method for treating local and distant tumors
WO2025264765A1 (en) * 2024-06-18 2025-12-26 Grann Pharmaceuticals Inc. Compositions and methods for modulating heat shock protein 70 activity for treatment of inflammatory diseases
CN120041511B (zh) * 2025-04-24 2025-09-02 浙江大学 IL-4受体激活剂或M-CSF受体激活剂在增强mRNA编辑巨噬细胞效率中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514060A (ja) * 2001-12-21 2005-05-19 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド アルブミン融合タンパク質
WO2018144775A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
JP2018532777A (ja) * 2015-10-22 2018-11-08 モデルナティーエックス， インコーポレイテッド 癌ワクチン
JP2018537521A (ja) * 2015-10-22 2018-12-20 モデルナティーエックス， インコーポレイテッド 広域インフルエンザウイルスワクチン
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
WO2019152557A1 (en) * 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
JPH09505474A (ja) 1993-11-26 1997-06-03 ブリテイツシユ・テクノロジー・グループ・リミテツド 翻訳エンハンサーｄｎａ
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
RU2749113C2 (ru) * 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514060A (ja) * 2001-12-21 2005-05-19 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド アルブミン融合タンパク質
JP2018532777A (ja) * 2015-10-22 2018-11-08 モデルナティーエックス， インコーポレイテッド 癌ワクチン
JP2018537521A (ja) * 2015-10-22 2018-12-20 モデルナティーエックス， インコーポレイテッド 広域インフルエンザウイルスワクチン
WO2018144775A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
WO2019152557A1 (en) * 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUR.J.IMMUNOL., vol. 49(1), JPN6024043943, January 2019 (2019-01-01), pages 179 - 191, ISSN: 0005575464 *

Also Published As

Publication number Publication date
AU2020368447A1 (en) 2022-04-28
US20240158458A1 (en) 2024-05-16
WO2021076805A1 (en) 2021-04-22
EP4045527A1 (en) 2022-08-24
CA3157859A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP2022552371A (ja) 免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用
JP2023510308A (ja) 寛容原性樹状細胞を作る方法
US20230027864A1 (en) Compositions and methods for delivery of agents to immune cells
JP7766583B2 (ja) 強化された薬剤送達のための組成物及び方法
JP7556848B2 (ja) ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物
JP2022543773A (ja) 免疫細胞へのｒｎａ干渉剤の送達のための組成物及び方法
JP2023103250A (ja) 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
JP2023512072A (ja) 代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用
JP2023526059A (ja) ｍＲＮＡ治療薬及びエフェクター分子を含むＬＮＰ組成物
JP2022552378A (ja) パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ
US20240401006A1 (en) Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
JP2024540170A (ja) インテグリンベータ－６をコードするポリヌクレオチド及びその使用方法
HK40050969A (en) Methods and compositions for treating cancer using mrna therapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250418